KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Total Liabilities (2018 - 2025)

Aurinia Pharmaceuticals' Total Liabilities history spans 8 years, with the latest figure at $170.3 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 1.68% year-over-year to $170.3 million; the TTM value through Dec 2025 reached $170.3 million, down 1.68%, while the annual FY2025 figure was $170.3 million, 1.68% down from the prior year.
  • Total Liabilities reached $170.3 million in Q4 2025 per AUPH's latest filing, up from $161.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $173.2 million in Q4 2024 to a low of $46.8 million in Q1 2021.
  • Average Total Liabilities over 5 years is $116.5 million, with a median of $155.6 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: skyrocketed 168.26% in 2023, then dropped 1.68% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $64.3 million in 2021, then increased by 1.79% to $65.4 million in 2022, then soared by 160.0% to $170.1 million in 2023, then rose by 1.8% to $173.2 million in 2024, then fell by 1.68% to $170.3 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Total Liabilities are $170.3 million (Q4 2025), $161.8 million (Q3 2025), and $167.3 million (Q2 2025).